Condition: Glioblastoma Multiforme · Anaplastic Astrocytoma · Fibrillary Astrocytomas · Sponsor: University of Miami
This study assesses the safety and efficacy of repeat monthly dosing of super-selective intra-arterial cerebral infusion (SIACI) of cetuximab and bevacizumab in patients \< 22 years of age.
This description comes directly from the study's public registry record.
Heather McCrea, MD · 305-585-3627 · hmccrea@med.miami.edu
Always discuss trial participation with your own doctor first.
| Jackson Memorial Hospital | Miami, Florida, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05956821